Product: XIYOUJI QINGZHI CAPSULE, 300mg, 20 count box
Reason for recall: Marketed without an Approved NDA/ANDA: Products found to contain undeclared sibutramine. Sibutramine was removed from the U.S. market for safety reasons, making these products unapproved new drugs.
Recall initiated: 20130520
Status: Terminated
Classification: Class I
Recall type: Voluntary: Firm initiated